Matthew Gline
Director, CEO · 4 filings · Latest: Sep 30, 2026
Roivant Sciences Ltd.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
ROIV | Matthew Gline | Director, CEO | Apr 16, 2026 | Sale | $29.16 | 289,774 | $8.4M | 16,736,116 | |
ROIV | Gline Matthew | — | Apr 16, 2026 | Proposed Sale | $29.16 | 289,774 | $8.4M | — | Apr 16 9:24 PM 144/A |
ROIV | Gline Matthew | — | Apr 16, 2026 | Proposed Sale | $29.16 | 289,774 | $8.4M | — | |
ROIV | Matthew Gline | Director, CEO | Mar 30, 2026 | Option Exercise | — | 97,319 | — | 17,384,400 | |
ROIV | Gline Matthew | — | Dec 15, 2025 | Proposed Sale | $21.68 | 1,740,000 | $37.7M | — | Dec 15 10:13 PM 144/A |
ROIV | Gline Matthew | — | Dec 15, 2025 | Proposed Sale | $21.68 | 1,740,000 | $37.7M | — | |
ROIV | Gline Matthew | — | Sep 23, 2024 | Proposed Sale | $11.79 | 1,983,257 | $23.4M | — |